11-108250966-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000051.4(ATM):c.1501C>T(p.Gln501*) variant causes a stop gained change. The variant allele was found at a frequency of 0.000000684 in 1,461,852 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000051.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.1501C>T | p.Gln501* | stop_gained | Exon 10 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251248Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135808
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461852Hom.: 0 Cov.: 36 AF XY: 0.00000138 AC XY: 1AN XY: 727224
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.Q501* pathogenic mutation (also known as c.1501C>T), located in coding exon 9 of the ATM gene, results from a C to T substitution at nucleotide position 1501. This changes the amino acid from a glutamine to a stop codon within coding exon 9. This alteration was identified in a cohort of pancreatic cancer patients (Hu C et al. JAMA. 2018 06;319:2401-2409). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
PVS1, PM2_Supporting, PM5_Supporting c.1501C>T, located in exon 10 of the ATM gene, is expected to result in loss of function by premature protein truncation before codon 501, p.(Gln501*). This alteration is expected to result in loss of function by premature protein truncation and nonsense-mediated mRNA decay (PVS1, PM5_Supporting). The variant allele was found in 1/268108 alleles in the population database gnomAD v2.1.1 (non cancer dataset) (PM2_Suppporting). The SpliceAI algorithm predicts no significant impact on splicing. To our knowledge, functional studies have not been reported for this variant. In addition, it has been reported in ClinVar database (5x pathogenic)and in the LOVD database (1x not classified). Based on currently available information, the variant c.1501C>T is classified as a pathogenic variant according to ClinGen-ATM Guidelines version v1.1. -
Ataxia-telangiectasia syndrome Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant has not been reported in the literature in individuals with ATM-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln501*) in the ATM gene. It is expected to result in an absent or disrupted protein product. -
Malignant tumor of urinary bladder Pathogenic:1
- -
not provided Pathogenic:1
ATM: PVS1, PM2 -
Familial cancer of breast Pathogenic:1
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at